Black Diamond Therapeutics, Inc. (BDTX) Q4 2024 Annual Earnings

BDTX·Reported March 6, 2025·Before market open

Diluted EPS came in at $-0.28, beat the $-0.31 consensus by $0.03.

Diluted EPS

$-0.28beat by $0.03

Consensus: $-0.31

SEC Filings

Earnings release8-K not filed yet

Annual report10-K · 0001701541-25-000016

Financial Snapshot

Trailing eight quarters through Q4 2024

View all metrics

Revenue

Net Income

Operating Cash Flow

EPS (Diluted)

Q4 2024 Earnings FAQ

Common questions about Black Diamond Therapeutics, Inc.'s Q4 2024 earnings report.

Black Diamond Therapeutics, Inc. (BDTX) reported Q4 2024 earnings on March 6, 2025 before market open.

Black Diamond Therapeutics, Inc. reported diluted EPS of $-0.28 for Q4 2024.

EPS beat the consensus estimate of $-0.31 by $0.03.

You can read the 10-K periodic report (0001701541-25-000016) directly on SEC EDGAR. The filing index links above go to sec.gov.